The first-in-human Phase 1 study described herein will evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of SPG302 in healthy volunteers and ALS participants
This study is a Phase 1 randomized, double-blind, placebo-controlled, single, and multiple ascending dose study in HV with food effect cohort, and a repeat dose expansion cohort(s) in participants with ALS. The study consists of 3 parts, as follows: * Part 1: SAD in HV with up to 6 cohorts including a food effect cohort. * Part 2: MAD over 5 days in HV with up to 5 cohorts * Part 3: ALS cohorts with once daily (QD) dosing over 28 day cycles
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Enrollment
88
Macquarie University
North Ryde, New South Wales, Australia
Royal Brisbane and Women's Hospital
Herston, Queensland, Australia
Flinders Medical center
Adelaide, South Australia, Australia
Nucleus Melbourne (healthy volunteers)
Melbourne, Victoria, Australia
Safety and tolerability in healthy volunteers (SAD cohort)
• Incidence, nature, and severity of treatment emergent adverse events (TEAEs) and serious adverse events (SAEs)
Time frame: 7 days
Safety and tolerability in healthy volunteers (SAD food effect cohort)
• Incidence, nature, and severity of treatment emergent adverse events (TEAEs) and serious adverse events (SAEs)
Time frame: 15 days
Safety and tolerability in healthy volunteers (MAD cohort)
• Incidence, nature, and severity of treatment emergent adverse events (TEAEs) and serious adverse events (SAEs)
Time frame: 12 days
Safety and tolerability in participants with ALS
• Incidence, nature, and severity of treatment emergent adverse events (TEAEs) and serious adverse events (SAEs)
Time frame: 60 days
Plasma pharmacokinetics of SPG302 in healthy volunteers (SAD cohort)
PK parameters of SPG302 on concentrations in plasma
Time frame: 7 days
Plasma pharmacokinetics of SPG302 in healthy volunteers (SAD food effect cohort)
Effects of food on SPG302 PK profile
Time frame: 15 days
Plasma pharmacokinetics of SPG302 in healthy volunteers (MAD cohort)
PK parameters of SPG302 on concentrations in plasma
Time frame: 12 days
Plasma pharmacokinetics of SPG302 in participants with ALS
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
PK parameters of SPG302 on concentrations in plasma
Time frame: 12mon
Clinical outcomes of multiple oral doses of SPG302 in participants with ALS
Spirometry
Time frame: 12 mon
Clinical efficacy measures of SPG302 in participants with ALS
The Amyotrophic Lateral Sclerosis Functional Rating Scale-revised (ALSFRS-R).
Time frame: 12 mon